News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceapro Inc. (CV:CZO) Announces Granting of Stock Options



9/1/2010 10:30:58 AM

EDMONTON, ALBERTA, CANADA--(Marketwire - August 31, 2010) - Ceapro Inc. (TSX VENTURE: CZO) today announced the granting of stock options to its directors, officers and certain employees for a total of 650,000 stock options, each with an exercise price of $0.10. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of five years from the date of grant.

Of note Chief Scientific Officer David Fielder and CFO Branko Jankovic each received 100,000 options, and directors Gilles Gagnon, Glenn Rourke, Ed Taylor, John Zupancic and Don Oborowsky each received 60,000 options. The granting of all options is subject to TSX Venture approval.

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. The commercial line of natural active ingredients include beta glucan, avenanthamides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin

peptides.

To learn more about Ceapro, visit www.ceapro.com

The TSX Venture Exchange nor its Regulation Services Provide (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Contacts:
Branko Jankovic
Chief Financial Officer
Ceapro Inc.
780-917-8376
bjankovic@ceapro.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES